StockTipsArenaBeta

BUY Eris Lifesciences Limited — Sandeep Jain, Tradeswift

BUYEris Lifesciences Limited

bySandeep Jain, TradeswiftHorizon: NA (inferred Swing (≤2wk))7 Sept 2026via Zee Business (Live)

Entry₹1,327.4Inferred
Target₹1,430
Total upside +7.73%
Stop loss₹1,270-4.32% risk
CMP₹1,324.311h ago
Active-0.23%+7.98%upside left 13d left
Follow Sandeep Jain for new calls(22% target hit, 46 closed calls)Get alertsWatch ERIS for new buy/sell callsGet alertsSee 115 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 8 Sept, 4:01 am IST
4 supporting1 neutral1 opposing
Supports the BUY call (4)

Eris Lifesciences: லாபத்தில் **73%** அதிரடி வளர்ச்சி - பங்கு முதலீட்டாளர்கள் கவனத்திற்கு!

NewsGoogle News·2 Sept · 5d ago

(opens in new tab)

Eris Lifesciences FY26 Revenue ₹3,129 Cr

NewsGoogle News·2 Sept · 5d ago

(opens in new tab)

Elara initiates coverage on Alkem, Eris, IPCA and Mankind. Check ratings and targets

NewsEt-Markets·28 Aug · 1w ago

(opens in new tab)

1 advisor has an active short-term BUY call on this stock

Advisor consensus · adjacent horizon·9 Jul · 2mo ago

Neutral / worth noting (1)

Eris Lifesciences schedules analyst meet with HBM Partners on August 27

NewsGoogle News·24 Aug · 2w ago

(opens in new tab)
Weighs against the BUY call (1)

MACD below its signal line — bearish momentum

Technicals · macd·7 Sept · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.